Four months after receiving a complete response letter from the U.S. FDA for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis, Sanofi SA received a positive opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results